Research catalog comparison
Tirzepatide vs Retatrutide
Tirzepatide and retatrutide have overlapping search interest but different receptor profiles. This page keeps the comparison narrow: current research-catalog availability, labeled quantities, and links to the separately sourced research summaries for each molecule.
Live catalog snapshot
In-stock listings only
Tirzepatide
- Lowest list price
- $22.99
- 5mg
- Suppliers
- 53
- Active offers
- 192
- Listed quantities
- 48
Retatrutide
- Lowest list price
- $29.50
- 10mg
- Suppliers
- 52
- Active offers
- 216
- Listed quantities
- 53
Lowest list prices can represent different quantities or forms and are not a direct unit-price comparison. The detailed pages show shipping, coupons, package details, and matching quantity options.
Key differences at a glance
| Comparison | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor profile | A dual GIP and GLP-1 receptor agonist. | A triple GIP, GLP-1, and glucagon receptor agonist studied in clinical research. |
| Catalog check | Compare matching tirzepatide quantities across active suppliers. | Compare matching retatrutide quantities across active suppliers. |
| Evidence caution | Use molecule-specific sources rather than transferring findings between compounds. | Use molecule-specific sources rather than transferring findings between compounds. |
Research summary starting points
Tirzepatide
Tirzepatide is a synthetic 39-amino acid polypeptide conjugated with a C20 fatty diacid moiety that functions as the first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Approved by the FDA in May 2022 for type 2 diabetes (brand name Mounjaro) and November 2023 for chronic weight management (brand name Zepbound), it demonstrates superior glycemic control and weight reduction compared to selective GLP-1 agonists. Clinical trials show dose-dependent weight loss of 15-21% and HbA1c reductions up to 2.58% over 40-72 weeks. The compound exhibits biased agonism, with greater affinity for GIP receptors and preferential cAMP signaling at GLP-1 receptors, contributing to enhanced beta-cell function and insulin sensitivity. In gray market contexts, tirzepatide is sold as a research chemical with significant quality and safety concerns, as unapproved versions lack FDA oversight for purity, sterility, and accurate dosing.
Read the sourced Tirzepatide overview →Retatrutide
Retatrutide (LY3437943) is a novel synthetic peptide that acts as a triple agonist at the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This 39-amino acid peptide represents a significant advancement in obesity pharmacotherapy, demonstrating superior weight loss efficacy compared to existing dual agonists like tirzepatide and single agonists like semaglutide. Phase 2 clinical trials have shown up to 24.2% body weight reduction at 48 weeks with the 12 mg dose, making it one of the most effective weight loss therapeutics in development. The triple agonist mechanism combines appetite suppression and enhanced insulin secretion (via GIP and GLP-1) with increased energy expenditure (via glucagon receptor activation), while also showing promising results for metabolic dysfunction-associated steatotic liver disease (MASLD) and glycemic control in type 2 diabetes.
Read the sourced Retatrutide overview →Common comparison questions
Are Tirzepatide and Retatrutide the same compound?
No. Tirzepatide and Retatrutide are distinct compounds. Compare their identities and evidence separately.
What is the lowest listed Tirzepatide price?
The lowest currently indexed in-stock Tirzepatide listing starts at $22.99 for 5mg. Compare matching quantities because package size and form affect price.
What is the lowest listed Retatrutide price?
The lowest currently indexed in-stock Retatrutide listing starts at $29.50 for 10mg. Compare matching quantities because package size and form affect price.
Comparison scope
Peptide Plus compares research-supplier catalog data. This page does not provide medical advice, dosing guidance, or a claim that either compound is appropriate for human use. All listed products are for research purposes only.